FXYD6-FXYD2

Q-omics provides the consensus-scored FXYD6-FXYD2 profile across patient tissues and cancer cell-line models. FXYD6-FXYD2 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in SCLC. Additionally, FXYD6-FXYD2 RNA expression shows 629 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight SCLC as cancer lineages where FXYD6-FXYD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes FXYD6-FXYD2 survival associations across molecular data types. FXYD6-FXYD2 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

FXYD6-FXYD2 data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	1	SCLC (37)	view →

This table ranks reproducible FXYD6-FXYD2 RNA expression–survival associations across cancer types. High FXYD6-FXYD2 expression shows favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for FXYD6-FXYD2 RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Tertile	II,III,IV	0.584	0.186	.003	37	view →

Pink = unfavorable, green = favorable. all 1 lineages →

FXYD6-FXYD2-SCLC (DFS)

Explore this curve interactively →